Study identifier:4522IL/0096
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events (AURORA). A double blind, randomised, phase 3b, parallel-group study to compare the effects of rosuvastatin with placebo on assessment of survival & cardiovascular events when given to subjects with end-stage renal failure on chronic haemodialysis treatment
Renal Failure
Phase 3
No
10mg Rosuvastatin, Placebo
All
2776
Interventional
50 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Nov 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to see if rosuvastatin helps to reduce the number of heart attacks, strokes and cardiovascular deaths in patients undergoing haemodialysis.
Location
Location
St Leonards, NSW, Australia
Location
Herston, QLD, Australia
Location
Bregenz, Austria
Location
Feldkirch-Tisis, Austria
Location
Graz, Austria
Location
Innsbruck, Austria
Location
Linz, Austria
Location
St. Poelten, Austria
Arms | Assigned Interventions |
---|---|
Experimental: Rosuvastatin 10mg | - |
Placebo Comparator: Placebo matching Placebo | - |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.